Immunisation and treatment - Societal benefits of immunising children

ESWI Airborne's Podcast

In this comprehensive exploration and conversation among distinguished experts in the field of childhood immunisation we listen to Paula Tähtinen, Clinical Lecturer, Paediatrics and Adolescent Medicine / Adjunct Professor, University of Turku and ESWI Board Member, Hanna Nohynek, Chief Medical Officer, Team Leader of Vaccine Programme Development at the National Institute for Health and Welfare, Finland, together with Sir Andrew Pollard, Professor of Paediatric Infection & Immunity at University of Oxford and the Director of the Oxford Vaccine Group succinctly cover the context of vaccinating against flu, RSV and COVID-19.

Is there a difference between recommending flu, RSV and COVID-19 vaccinations in children? What is meant by preventing secondary diseases and other societal wider benefits? What factors are considered before a country introduces a new vaccine in its national vaccination programme? How long does it usually take before a vaccine is rolled-out? And who are the happy wheezers?